A Study To Evaluate The Safety And Tolerability Of The Covalent Phosphoinositide-3-Kinase (Pi3k)-Alpha Inhibitor, Tos-358, In Adult Subjects With Select Solid Tumors
Posted Date: Apr 26, 2024
- Investigator: Davendra Sohal
- Specialties:
- Type of Study: Drug
The goal of this clinical trial is to evaluate the safety of TOS-358 in adults with select solid tumors: colorectal cancer, gastric cancer, non-small cell lung cancer, human epidermal growth factor receptor 2 (HER2) negative breast cancer, squamous cell carcinoma of the head and neck, urothelial cancer, or select gynecologic cancers (ovarian cancer, cervical cancer, or endometrial cancer) with known PIK3CA mutations or amplifications.
Criteria:
Null
Keywords:
Colorectal Cancer, Gastric Cancer, Her2 Negative Breast Cancer
For More Information:
Kayla Webb
NULL
cancer@uchealth.com